First-line chemotherapy plus immune checkpoint inhibitors or bevacizumab in advanced non-squamous non-small-cell lung cancer without EGFR mutations or ALK fusions

Panpan Jiang; Luying Geng; Ziyang Mao; Qinyang Wang; Wenjuan Wang; Min Jiao; Yu Yao; Nanzheng Chen; Jia Zhang; Kejun Nan; Yuan Shen; Hui Guo; Lili Jiang

doi:10.2217/imt-2021-0112

First-line chemotherapy plus immune checkpoint inhibitors or bevacizumab in advanced non-squamous non-small-cell lung cancer without EGFR mutations or ALK fusions

Panpan Jiang
, Luying Geng
, Ziyang Mao
, Qinyang Wang
, Wenjuan Wang
, Min Jiao
, Yu Yao
, Nanzheng Chen
, Jia Zhang
, Kejun Nan
, Yuan Shen
, Hui Guo
, Lili Jiang

Health Science Center

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Aim: To compare the efficacy and safety of first-line chemotherapy (Chemo) plus immune checkpoint inhibitors (ICIs) or bevacizumab (Bev) in advanced non-squamous non-small-cell lung cancer without EGFR mutations or ALK fusions. Methods: A network meta-analysis was conducted to synthesize relative treatment outcomes. Results: Chemo + ICIs is superior to Chemo + Bev in both overall survival (hazard ratio: 0.92; 95% CI: 0.88-0.96) and progression-free survival (hazard ratio: 0.93; 95% CI: 0.90-0.97), with comparable severe adverse events. However, for patients with liver metastasis, Chemo + Bev has a 59.8% probability of providing better overall survival benefit. For specific regimens, pembrolizumab + Chemo showed an absolute advantage over other regimens. Conclusion: First-line Chemo + ICIs is superior to Chemo + Bev in advanced non-squamous non-small-cell lung cancer except for patients with liver metastasis.

Original language	English
Pages (from-to)	445-457
Number of pages	13
Journal	Immunotherapy
Volume	14
Issue number	6
DOIs	https://doi.org/10.2217/imt-2021-0112
State	Published - Apr 2022

Keywords

advanced non-squamous non-small-cell lung cancer
bevacizumab
first-line
immune checkpoint inhibitors
network meta-analysis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/imt-2021-0112

Cite this

Jiang, P., Geng, L., Mao, Z., Wang, Q., Wang, W., Jiao, M., Yao, Y., Chen, N., Zhang, J., Nan, K., Shen, Y., Guo, H., & Jiang, L. (2022). First-line chemotherapy plus immune checkpoint inhibitors or bevacizumab in advanced non-squamous non-small-cell lung cancer without EGFR mutations or ALK fusions. Immunotherapy, 14(6), 445-457. https://doi.org/10.2217/imt-2021-0112

@article{5ef9ac7977d54bc09b65b484e38e54c6,

title = "First-line chemotherapy plus immune checkpoint inhibitors or bevacizumab in advanced non-squamous non-small-cell lung cancer without EGFR mutations or ALK fusions",

abstract = "Aim: To compare the efficacy and safety of first-line chemotherapy (Chemo) plus immune checkpoint inhibitors (ICIs) or bevacizumab (Bev) in advanced non-squamous non-small-cell lung cancer without EGFR mutations or ALK fusions. Methods: A network meta-analysis was conducted to synthesize relative treatment outcomes. Results: Chemo + ICIs is superior to Chemo + Bev in both overall survival (hazard ratio: 0.92; 95\% CI: 0.88-0.96) and progression-free survival (hazard ratio: 0.93; 95\% CI: 0.90-0.97), with comparable severe adverse events. However, for patients with liver metastasis, Chemo + Bev has a 59.8\% probability of providing better overall survival benefit. For specific regimens, pembrolizumab + Chemo showed an absolute advantage over other regimens. Conclusion: First-line Chemo + ICIs is superior to Chemo + Bev in advanced non-squamous non-small-cell lung cancer except for patients with liver metastasis.",

keywords = "advanced non-squamous non-small-cell lung cancer, bevacizumab, first-line, immune checkpoint inhibitors, network meta-analysis",

author = "Panpan Jiang and Luying Geng and Ziyang Mao and Qinyang Wang and Wenjuan Wang and Min Jiao and Yu Yao and Nanzheng Chen and Jia Zhang and Kejun Nan and Yuan Shen and Hui Guo and Lili Jiang",

note = "Publisher Copyright: {\textcopyright} 2022 Future Medicine Ltd.",

year = "2022",

month = apr,

doi = "10.2217/imt-2021-0112",

language = "英语",

volume = "14",

pages = "445--457",

journal = "Immunotherapy",

issn = "1750-743X",

publisher = "Taylor and Francis Ltd.",

number = "6",

}

TY - JOUR

T1 - First-line chemotherapy plus immune checkpoint inhibitors or bevacizumab in advanced non-squamous non-small-cell lung cancer without EGFR mutations or ALK fusions

AU - Jiang, Panpan

AU - Geng, Luying

AU - Mao, Ziyang

AU - Wang, Qinyang

AU - Wang, Wenjuan

AU - Jiao, Min

AU - Yao, Yu

AU - Chen, Nanzheng

AU - Zhang, Jia

AU - Nan, Kejun

AU - Shen, Yuan

AU - Guo, Hui

AU - Jiang, Lili

PY - 2022/4

Y1 - 2022/4

N2 - Aim: To compare the efficacy and safety of first-line chemotherapy (Chemo) plus immune checkpoint inhibitors (ICIs) or bevacizumab (Bev) in advanced non-squamous non-small-cell lung cancer without EGFR mutations or ALK fusions. Methods: A network meta-analysis was conducted to synthesize relative treatment outcomes. Results: Chemo + ICIs is superior to Chemo + Bev in both overall survival (hazard ratio: 0.92; 95% CI: 0.88-0.96) and progression-free survival (hazard ratio: 0.93; 95% CI: 0.90-0.97), with comparable severe adverse events. However, for patients with liver metastasis, Chemo + Bev has a 59.8% probability of providing better overall survival benefit. For specific regimens, pembrolizumab + Chemo showed an absolute advantage over other regimens. Conclusion: First-line Chemo + ICIs is superior to Chemo + Bev in advanced non-squamous non-small-cell lung cancer except for patients with liver metastasis.

AB - Aim: To compare the efficacy and safety of first-line chemotherapy (Chemo) plus immune checkpoint inhibitors (ICIs) or bevacizumab (Bev) in advanced non-squamous non-small-cell lung cancer without EGFR mutations or ALK fusions. Methods: A network meta-analysis was conducted to synthesize relative treatment outcomes. Results: Chemo + ICIs is superior to Chemo + Bev in both overall survival (hazard ratio: 0.92; 95% CI: 0.88-0.96) and progression-free survival (hazard ratio: 0.93; 95% CI: 0.90-0.97), with comparable severe adverse events. However, for patients with liver metastasis, Chemo + Bev has a 59.8% probability of providing better overall survival benefit. For specific regimens, pembrolizumab + Chemo showed an absolute advantage over other regimens. Conclusion: First-line Chemo + ICIs is superior to Chemo + Bev in advanced non-squamous non-small-cell lung cancer except for patients with liver metastasis.

KW - advanced non-squamous non-small-cell lung cancer

KW - bevacizumab

KW - first-line

KW - immune checkpoint inhibitors

KW - network meta-analysis

UR - https://www.scopus.com/pages/publications/85126836881

U2 - 10.2217/imt-2021-0112

DO - 10.2217/imt-2021-0112

M3 - 文章

C2 - 35259921

AN - SCOPUS:85126836881

SN - 1750-743X

VL - 14

SP - 445

EP - 457

JO - Immunotherapy

JF - Immunotherapy

IS - 6

ER -

First-line chemotherapy plus immune checkpoint inhibitors or bevacizumab in advanced non-squamous non-small-cell lung cancer without EGFR mutations or ALK fusions

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this